Amryt Pharma Plc ADR (AMYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -42,335 | -21,540 | -14,491 | 1,000 | -40,545 |
| Depreciation Amortization | 53,522 | 33,471 | 16,389 | 55,162 | 36,879 |
| Income taxes - deferred | -9,335 | -11,524 | -11,105 | -9,268 | -15,677 |
| Accounts receivable | 3,287 | 3,672 | 6,538 | -3,543 | -2,609 |
| Accounts payable and accrued liabilities | -17,205 | -23,058 | -13,867 | 11,758 | -108,468 |
| Other Working Capital | -29,883 | -32,242 | -13,718 | -7,842 | -113,031 |
| Other Operating Activity | 42,788 | 37,723 | 22,713 | -31,727 | 151,557 |
| Operating Cash Flow | $839 | $-13,498 | $-7,541 | $15,540 | $-91,894 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -892 | -668 | -423 | -729 | -92 |
| Net Acquisitions | N/A | N/A | N/A | 107,942 | 107,942 |
| Purchase Sale Intangibles | -109 | N/A | N/A | -816 | -830 |
| Other Investing Activity | -16,182 | 25 | 2 | -811 | -827 |
| Investing Cash Flow | $-17,074 | $-643 | $-421 | $106,402 | $107,023 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 98,344 | 98,344 | 98,344 | N/A | N/A |
| Debt Repayment | -98,761 | -98,761 | -95,469 | -116,629 | N/A |
| Common Stock Issued | 1,311 | 1,063 | 1,063 | 4,701 | -116 |
| Common Stock Repurchased | -2,197 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -9,909 | -6,801 | -6,613 | -13,498 | -8,386 |
| Financing Cash Flow | $-11,212 | $-6,155 | $-2,675 | $-125,426 | $-8,502 |
| Exchange Rate Effect | -2,185 | -2,003 | -175 | -2,282 | -2,248 |
| Beginning Cash Position | 113,032 | 113,032 | 112,982 | 118,798 | 118,798 |
| End Cash Position | 83,400 | 90,733 | 102,170 | 113,032 | 123,177 |
| Net Cash Flow | $-29,632 | $-22,299 | $-10,812 | $-5,766 | $4,379 |
| Free Cash Flow | |||||
| Operating Cash Flow | 839 | -13,498 | -7,541 | 15,540 | -91,894 |
| Capital Expenditure | -892 | -668 | -423 | -729 | -92 |
| Free Cash Flow | -53 | -14,166 | -7,964 | 14,811 | -91,986 |